Physician profile
Antonio Reyes
NPI 1174584809
$7,508.06
in general payments reported to CMS, 2019-2025
25 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $275 · 2021: $371 · 2022: $536 · 2023: $2,625 · 2024: $426 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790 · Travel and Lodging: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.29 |
| Travel and Lodging | $1,601.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $2,210.85 | 2023 | Nanoknife |
| Intuitive Surgical, INC. | $2,087.70 | 2019-2024 | Da Vinci Surgical System |
| Coloplast Corp | $1,300.76 | 2019-2025 | Titan |
| Janssen Biotech, INC. | $464.33 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $220.88 | 2022-2025 | |
| Procept Biorobotics Corporation | $192.00 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Boston Scientific Corporation | $147.82 | 2021-2025 | Lithovue Elite, Ams 700, Lithovue |
| Astellas Pharma US INC | $113.68 | 2020-2023 | Myrbetriq, Veozah |
| Teleflex LLC | $113.62 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $89.89 | 2024-2025 | Prolaris, Myrisk |
| Allergan, INC. | $82.92 | 2019-2021 | |
| Rochester Medical Corporation | $78.30 | 2020 | |
| Endo Pharmaceuticals INC. | $64.70 | 2021 | |
| Myovant Sciences INC. | $58.02 | 2021 | |
| Tolmar, INC. | $41.27 | 2024-2025 | Eligard, Jatenzo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $39.50 | 2019-2021 | |
| Biotissue Holdings INC. | $38.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $30.58 | 2025 | |
| Dendreon Pharmaceuticals LLC | $26.83 | 2025 | Provenge |
| Pfizer INC. | $23.58 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $23.28 | 2020 | |
| Merck Sharp & Dohme LLC | $21.18 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.97 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $12.44 | 2022 | |
| Zyla Life Sciences, INC. | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.